Abstracts

IMPACT OF TREATMENT INTERRUPTION ON COLONIC MUCOSA IN ACUTELY TREATED PARTICIPANTS

Despite antiretroviral therapy (ART) initiation during acute HIV infection and viral suppression for years, most individuals experience viral rebound shortly after treatment interruption. The major obstacles to HIV cure are tissue reservoirs that are established early during infection. We had the unique opportunity to analyze sigmoid colon biopsies prior to and during analytical treatment interruption…

HIV-1 RESERVOIRS ESTABLISHED PRIOR TO THERAPY CONTRIBUTE TO REBOUND VIRUS

Genetically-characterising rebound virus during analytical treatment interruptions (ATI) will further our understanding of the persistent HIV-1 reservoir that is the barrier to a cure. Therefore, we employed a novel long-range RNA sequencing method to investigate the genetic composition of HIV-1 virions within ATI plasma samples from participants treated during acute infection. First, we employed the…

Vpr SHAPES THE PROVIRAL LANDSCAPE AND POLYCLONAL HIV-1 REACTIVATION PATTERNS IN VITRO

Cell culture models suggest that the HIV-1 viral protein R (Vpr) is dispensable for latency establishment. However, whether Vpr affects the persistent proviral landscape and responsiveness to latency reversing agents (LRAs) is unclear. Here, integration site landscape, clonal dynamics, and latency reversal effects of Vpr were studied by comparing barcoded vpr+ and vpr- populations arising…

HIV-1 VIRAL RESERVOIR DISRUPTION WITH PANOBINOSTAT AND IFN-?

Current antiretroviral therapies (ART) are unable to eradicate HIV-1, mainly because the virus persists in latently infected cells that can fuel viral rebound after treatment interruption. Pharmacological reactivation of viral transcription may sensitize viral reservoir cells to immune-mediated killing and reduce the long-term persistence of virus-infected CD4+ T cells. The ACTIVATE study is a prospective,…

IMPACT OF INFLUENZA AND PNEUMOCOCCUS VACCINES ON CELLULAR HIV RNA TRANSCRIPTION

We sought to determine if standard influenza and pneumococcus vaccines can be used to stimulate HIV reservoirs during suppressive antiretroviral therapy (ART). Persons with HIV infection on suppressive ART (N=54) were enrolled in a randomized, double-blinded, placebo-controlled, cross-over trial of two clinically recommended vaccines. For three cycles, Placebo, Pneumovax®23, and Fluarix® vaccines were administered in…

POST-TREATMENT CONTROLLERS LIMIT COMPLETED AND SPLICED HIV TRANSCRIPTS AFTER ATI

The mechanisms that allow post-treatment controllers (PTC) to limit viral replication after antiretroviral therapy interruption (ATI) remain unclear. Compared to noncontrollers (NC), we hypothesized that PTC would show greater blocks to HIV transcriptional completion and splicing following ATI. We measured levels of cell-associated (CA) initiated (TAR), 5′-elongated (Long), mid-elongated (Pol), completed (PolyA), and multiply-spliced (TatRev)…

IMMUNOLOGICAL AND GLYCOMIC CORRELATES OF TIME-TO-HIV-REBOUND IN VIREMIC CONTROLLERS

Analytic treatment interruption (ATI) is the most reliable way to evaluate the efficacy of potential HIV cure strategies but require lengthy and intensive monitoring. Identifying pre-ATI correlates of time-to-HIV-rebound (TTHR) after antiretroviral therapy (ART) cessation can significantly aid the development of a functional cure to HIV infection. We examined the associations between TTHR and pre-ATI…